First-trimester preterm preeclampsia prediction with metabolite biomarkers: differential prediction according to maternal body mass index
Cork, Ireland, February 2023 – Metabolomic Diagnostics is delighted to share our most recent publication in the American Journal of…
Read MoreDr Greg Fitzgibbon joins Metabolomic Diagnostics as Clinical Laboratory Director
Cork, Ireland, May 2022 – Metabolomic Diagnostics is delighted to welcome Dr Greg Fitzgibbon to the team as Clinical Laboratory…
Read MoreMay Is Preeclampsia Awareness Month
Metabolomic Diagnostics Is Working To Raise Preeclampsia Awareness Cork, Ireland, May 2022 –Metabolomics Diagnostics working to raise preeclampsia awareness. Metabolomics…
Read MoreMetabolomics Diagnostics Announces Partnership With Preeclampsia Foundation
Cork, Ireland, May 2022 – Irish diagnostics company Metabolomics Diagnostics announces its corporate partnership with the Preeclampsia Foundation. The Preeclampsia…
Read MoreMetabolomics Diagnostics Announces Partnership with US company Renegade.bio to Launch Preeclampsia Test in USA Market
Metabolomics Diagnostics Announces Partnership with US company Renegade.bio to Launch Preeclampsia Test in USA Market Cork Ireland and San Francisco…
Read MoreMetabolomic Diagnostics appoints Dr. Ana Panigassi as Head of Clinical Affairs
Metabolomic Diagnostics, the Ireland based, deep tech medical diagnostics company, today announced the appointment of Dr. Ana Panigassi to the…
Read More